Blackstone

Apogee bags $1.3B royalty funding deal to advance eczema hopeful

Apogee has secured a promise of up to $1.3 billion from Blackstone Life Sciences as the biotech gears up to take its anti-IL-13 antibody into phase 3.

James Waldron May 27, 2026 8:57am

Blackstone Invests $250M in Anagram to reduce CF pill burden

May 7, 2026 10:36am

Longtime Hologic CEO MacMillan to retire as $18.3B deal closes

Apr 7, 2026 9:57am

Blackstone closes record $6.3B life sciences fund

Mar 30, 2026 1:50pm

Teva's $400M Blackstone deal to fund Sanofi-partnered IBD drug

Mar 4, 2026 3:07am

Ovid eyes next chapter with CEO transition—Chutes & Ladders

Nov 14, 2025 8:30am